Reliance Industries Q4FY21: Strong contribution from digital businesses likely to offset probable weakness in cyclical sectors
RIL reported a strong sequential improvement for its Oil derivative and retail segments. Petrochemicals exhibited elevated product spreads and in the case of retail, the trend of sequential recovery continued across consumption baskets. Jio continued to report strong numbers despite lower ARPU
Syngene: Heavy investment phase makes it a long-term play
Beyond contract research, another trend to watch for Syngene is the pick-up in contract manufacturing business in biologics and APIs
Fed: The US economy has just got vaccinated
Even though the next few months of payroll data are expected to be exceptionally good, the Fed will give due credence to the weak macroeconomic situation elsewhere in the world before hinting at a rate hike cycle
A play on likely outperformance of agro-chemical sector in near term
Rallis' focus on the contract manufacturing business and filling portfolio gaps are a key watch
What is the endgame for the second wave? How should investors position themselves? Part-2
Given improved demand scenario in developed markets and ebbing of health crises elsewhere, India’s export oriented sectors – IT, pharma and chemicals – are expected to outperform in the short to medium run
What is the endgame for the second wave? How should investors position themselves? Part-1
Countries having high coverage of COVID jabs have seen a sharp decline in death rates as the vaccination coverage picked up
Phillips Carbon: Second wave slams brakes on recovery theme
The second wave of COVID is likely to have an impact on domestic demand for discretionary players in auto and consumer durables. Phillips Carbon is one such name
Bhansali Engineering Q4: Margins likely to moderate in near term; valuation fair
The drivers to watch Bhansali Engineering are a pick-up in the end-market demand and a traction in greenfield capex plan
Deregulation of vaccine rollout: What it means for pharma players
Dr Reddy’s, Gland Pharma, Strides, Cadila, Aurobindo are some of the names that merit a close watch as operating leverage plays out
Solara Active: Aurore deal to act as a booster for CRAMS; accumulate
The Aurore deal should help Solara in ramping up CRAMS portfolio, diversifying the API product basket and also aiding backward integration
What ‘second wave’ means for investors in Indian pharma
Multi-year opportunity awaits Indian vaccine manufacturers such as DRL, Gland Pharma, Aurobindo Pharma and Cadila Pharma
CDMO leader ready to straddle entire pharma value chain
Except phosgenation and fluorination, Suven Pharma is capable of handling every other chemistry. This adds to the scope for contract engagements in speciality chemicals and clinical development for pharma
Laxmi Organic: Investment horizon should match business transformation time span
Laxmi Organic is certainly on a transformation mode, and, hence, investors need to be patient enough to witness the change in business mix.
Anupam Rasayan IPO: Has it lost the case with weak listing?
Anupam though 1/10th the size of PI Industries, appears to be its good proxy in the field of custom synthesis of agro-chemicals. One of the things which strikes us is the growing export exposure to the lucrative Japanese market.
Bodal Chemicals: On transformation from a dyes major to a diversified play
Business case for the new capex and acquisition of Bodal Chemicals appears promising, given the import substitution play and higher applications of benzene-based chemicals
Laxmi Organic IPO: A leader in basic chemicals, doubling down on speciality
Re-rating driver for Laxmi Organic depends on success in fluorospeciality, which is likely to be margin-accretive
Anupam Rasayan IPO: A tiny version of PI Industries, diversifying beyond agro-chem
One eye catcher is the growing export exposure for Anupam Rasayan to the lucrative Japanese market
Heranba, a short-term pop or long-term compounder?
Post listing gains, should we look beyond Heranba in agro-chem?
Atul and Amal: When basic chemicals get special
Basic chemical player Amal warrants investors’ attention just as APIs in the pharma space are getting policy attention
Rain Industries: Time to reap 'end of capex cycle'
Though the Rain stock has firmed up since our last note by 22 per cent, we remain constructive as the valuations are still reasonable
NSE Trading Halt: Outage calls for regulatory action to restore retail investor confidence
Retail equity participants are most vulnerable to the harmful effects of technical failures in the financial market
Aarti Industries: Conviction backed by heavy capex
Capex projects for Aarti Industries are on track and are backed by a budget of about Rs 1,000-1,200 crore per annum for the next 4-5 years
Heranba IPO: A short-term pop or a long-term compounder?
Coming to valuations, Heranba appears reasonably priced, given its return ratios and margin profile. The key aspect that differentiates is that China is a major export destination for the company.
What has this Vitamin D API maker to offer beyond Covid opportunity?
Fermenta Biotech’s near-term growth for the Human Vitamin D3 volume is contingent on commissioning of the Dahej plant in the current quarter
- Trade setup for Monday: Top 15 things to know before Opening Bell Watch more
- Miles To Go | Visit Gulmarg: Khyber Himalayan Resort & Spa Watch more
- No WhatsApp, no social media. Only calls and SMS. How Nandan Nilekani keeps calm in the digital world Watch more
- Ladies & Gentlemen, The Weekend! Watch more